6-(3-Chloro-4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone | 56872-24-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 6-(3-Chloro-4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone
• 英文别名: 6-(3-chloro-4-hydroxy-phenyl)-4,5-dihydro-2H-pyridazin-3-one；3-(3-chloro-4-hydroxyphenyl)-4,5-dihydro-1H-pyridazin-6-one
• CAS: 56872-24-3
• 化学式: C₁₀H₉ClN₂O₂
• 分子量: 224.647
• InChiKey: ZGIMFGCGLBXFHW-UHFFFAOYSA-N

物化性质

• 熔点：
  265-267 °C
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  61.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(3-Chloro-4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone 生成 6-[3-chloro-4-(ethoxycarbonylmethoxy)phenyl]-4,5-dihydro-3(2H)-pyridazinone
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Pyridazinone derivatives, their preparation and use
  申请人：Sankyo Company Limited

  公开号：US04914093A1

  公开（公告）日：1990-04-03

  Compounds of formula (I): ##STR1## (wherein Q is oxygen or sulfur, the dotted line is a single or double bond, A is alkylene, and R.sup.1 -R.sup.5 are a variety of atoms or organic groups) have excellent ability to potentiate myocardial contractivity and a variety of other properties, and can be used to treat cardiac disorders.

  式(I)的化合物：##STR1##（其中Q是氧或硫，虚线是单键或双键，A是烷基，R.sup.1-R.sup.5是各种原子或有机基团）具有优异的增强心肌收缩能力和多种其他性质，可用于治疗心脏疾病。
• Pyridazinones having cardiotonic and beta blocking activities
  申请人：Glaxo Inc.

  公开号：US05096904A1

  公开（公告）日：1992-03-17

  Pyridazinones of the following formula (I): ##STR1## where R.sup.1 -R.sup.4 are a variety of substituents and L is a linking group, a pharmaceutical composition for treating congestive heart failure, novel intermediates, methods for such treatment and processes for preparing compounds of formula (I).

  以下式（I）的吡啶并嗪酮：##STR1##其中R.sup.1 -R.sup.4是各种取代基，L是连接基团，用于治疗充血性心力衰竭的药物组合物，新颖的中间体，用于该治疗的方法以及制备式（I）化合物的过程。
• Dihydropyridine vasodilator agents
  申请人：Glaxo Inc.

  公开号：US05100892A1

  公开（公告）日：1992-03-31

  Compounds of the following formula (I): ##STR1## where R.sup.1 and R.sup.2 are alkyl or cycloalkyl, which may be substituted, R.sup.4 is aryl such as phenyl which may be substituted, L is a direct bond or an oxygen containing linking group, R is a hydrogen, alkyloxy, alkyl, halogen or haloalkyl and Het is a pyridinyl or pyridazinyl group. The compounds can be used antihypertensives or myocardial relaxants. Also part of the invention are pharmaceutical compositions, intermediates and methods of synthesis.

  以下式子(I)的化合物：##STR1## 其中R.sup.1和R.sup.2是烷基或环烷基，可以被取代，R.sup.4是苯基，例如苯基可以被取代，L是直接键或含氧连结基，R是氢，烷氧基，烷基，卤素或卤代烷基，Het是吡啶基或吡嗪基。这些化合物可用作降压剂或心肌松弛剂。此外，本发明还涉及制药组合物、中间体和合成方法。
• Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having
  申请人：Glaxo Inc.

  公开号：US05204463A1

  公开（公告）日：1993-04-20

  Pyridazinones of the following formula (I): ##STR1## where R.sup.1 -R.sup.4 are a variety of substituents and L is a linking group, a pharmaceutical composition for treating congestive heart failure, novel intermediates, methods for such treatment and processes for preparing compounds of formula (I).

  以下式(I)的吡啶并嗪酮：##STR1## 其中R.sup.1-R.sup.4是各种取代基，L是连接基团，用于治疗充血性心力衰竭的药物组合物，新的中间体，用于该治疗的方法以及制备式(I)化合物的过程。
• Kinetic resolution of pyridazinones using lipase
  申请人：Glaxo Inc.

  公开号：US05053338A1

  公开（公告）日：1991-10-01

  A kinetic resolution of pyridazinones of the following formula (A): ##STR1## where R.sup.1 is alkyl by enzymatic hydrolysis results in good optical purity of the phenolic product. This is significant considering the distance in the molecule (A) from the C-5 chiral center to the site of hydrolysis.

  以下化学式（A）的吡啶并氮酮：##STR1## 其中R.sup.1是烷基，通过酶水解的动力学分辨可得到良好的酚类产物光学纯度。考虑到分子（A）中C-5手性中心到水解部位的距离，这一结果具有重要意义。